189 related articles for article (PubMed ID: 23448094)
1. Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990.
Milanović D; Firat E; Grosu AL; Niedermann G
Radiat Oncol; 2013 Feb; 8():42. PubMed ID: 23448094
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
[TBL] [Abstract][Full Text] [Related]
3. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
4. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
5. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
[TBL] [Abstract][Full Text] [Related]
6. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
7. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Lamottke B; Kaiser M; Mieth M; Heider U; Gao Z; Nikolova Z; Jensen MR; Sterz J; von Metzler I; Sezer O
Eur J Haematol; 2012 May; 88(5):406-15. PubMed ID: 22309072
[TBL] [Abstract][Full Text] [Related]
8. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.
Chu SH; Karri S; Ma YB; Feng DF; Li ZQ
Neuro Oncol; 2013 Jul; 15(7):880-90. PubMed ID: 23519742
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
[TBL] [Abstract][Full Text] [Related]
11. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.
Zitzmann K; Ailer G; Vlotides G; Spoettl G; Maurer J; Göke B; Beuschlein F; Auernhammer CJ
Int J Oncol; 2013 Dec; 43(6):1824-32. PubMed ID: 24100469
[TBL] [Abstract][Full Text] [Related]
13. Iron-oxide nanoparticles target intracellular HSP90 to induce tumor radio-sensitization.
Shetake NG; Kumar A; Pandey BN
Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):857-869. PubMed ID: 30794824
[TBL] [Abstract][Full Text] [Related]
14. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
Stühmer T; Iskandarov K; Gao Z; Bumm T; Grella E; Jensen MR; Einsele H; Chatterjee M; Bargou RC
Anticancer Res; 2012 Feb; 32(2):453-62. PubMed ID: 22287732
[TBL] [Abstract][Full Text] [Related]
15. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
16. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
17. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
19. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
Schilling D; Garrido C; Combs SE; Multhoff G
Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
[TBL] [Abstract][Full Text] [Related]
20. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
